Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Volatility mars market indices
Wed, 28 Mar 01:30 pm

After a weak opening, Indian stock markets turned positive for a brief period, but slipped below the dotted line in the last two trading hours as selling intensified. Barring FMCG and capital goods, all the sectoral indices are trading negative. Consumer durables, realty and banking stocks are the biggest losers.

The BSE-Sensex is trading down 73 points and NSE-Nifty is trading down 24 points. Both BSE Mid cap index and BSE Small cap indices are down 0.4% and 0.6% respectively. The rupee is trading at 50.9 to the US dollar.

Auto stocks are trading mixed with Tube Investments and Escorts being the biggest gainers and Maharashtra Scooters and Eicher Motor being the biggest losers. As per a leading financial daily, Hero MotoCorp is focusing on developing multiple technological tie-ups after it ended its collaboration with Honda, a year ago. As per the company, complete shift to the Hero brand will take 6-12 months. The company recently entered an agreement with US-based Eric Buell Racing (EBR) having a presence in high-end racing bikes. The company wants to adapt EBR's technology for mid-segment bikes beyond 200 cc which are likely to be launched by 2013; while bikes on complete EBR platform would be launched by 2013-14. Hero Motocorp does not want to limit its technological partnership to a single company but is looking for 3-4 tie-ups with technical experts. The company is working with AVL & Ricardo for engines and wants to seek technological support for styling of bikes and for small engines in the 100-125 cc range. The stock is down 0.8%.

Majority of the Indian pharma stocks have been trading positive with Strides Acrolab and Elder Pharma trading the strongest. As per a leading financial daily, Dr Reddy's will be going for a joint venture (JV) with Japan-based Fujifilm. The JV will set up a manufacturing facility to develop and produce generic drugs for the Japanese market and is expected to benefit from Fujifilm's advanced quality control technologies and DRL's expertise in cost competitive production technologies for active pharmaceutical ingredients and formulations. It will take 2-3 years for the company to come out with products. However, the company will have to obtain product approvals from Japansese authorities before the launch. A definitive agreement regarding this is expected to be signed by June 2012. The stakes of Fujifilm and DRL will be 51% and 49% respectively as per the agreement. DRL stock is up 2.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Volatility mars market indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.